{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,31]],"date-time":"2026-01-31T08:16:17Z","timestamp":1769847377910,"version":"3.49.0"},"reference-count":35,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2015,4,11]],"date-time":"2015-04-11T00:00:00Z","timestamp":1428710400000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Ophthalmol"],"published-print":{"date-parts":[[2015,12]]},"DOI":"10.1186\/s12886-015-0019-x","type":"journal-article","created":{"date-parts":[[2015,4,10]],"date-time":"2015-04-10T00:32:51Z","timestamp":1428625971000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Bevacizumab treatment for neovascular age-related macular degeneration in the setting of a clinic: \u201creal life\u201d long-term outcome"],"prefix":"10.1186","volume":"15","author":[{"given":"Gala","family":"Beykin","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michelle","family":"Grunin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Edward","family":"Averbukh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eyal","family":"Banin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yitzchak","family":"Hemo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Itay","family":"Chowers","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2015,4,11]]},"reference":[{"key":"19_CR1","doi-asserted-by":"crossref","first-page":"1388","DOI":"10.1016\/j.ophtha.2012.03.053","volume":"1197","author":"DF Martin","year":"2012","unstructured":"Comparison of Age-related Macular Degeneration Treatments Trials Research G, Martin DF, Maguire MG, Fine SL, Ying GS, Jaffe GJ, et al. Ranibizumab and bevacizumab for treatment of neovascular age-related macular degeneration: two-year results. Ophthalmology. 2012;1197:1388\u201398.","journal-title":"Ophthalmology"},{"key":"19_CR2","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1016\/j.ophtha.2008.10.018","volume":"1161","author":"DM Brown","year":"2009","unstructured":"Brown DM, Michels M, Kaiser PK, Heier JS, Sy JP, Ianchulev T, et al. Ranibizumab versus verteporfin photodynamic therapy for neovascular age-related macular degeneration: Two-year results of the ANCHOR study. Ophthalmology. 2009;1161:57\u201365.","journal-title":"Ophthalmology"},{"key":"19_CR3","doi-asserted-by":"publisher","first-page":"1419","DOI":"10.1056\/NEJMoa054481","volume":"35514","author":"PJ Rosenfeld","year":"2006","unstructured":"Rosenfeld PJ, Brown DM, Heier JS, Boyer DS, Kaiser PK, Chung CY, et al. Ranibizumab for neovascular age-related macular degeneration. N Engl J Med. 2006;35514:1419\u201331.","journal-title":"N Engl J Med"},{"key":"19_CR4","first-page":"1399","volume":"1197","author":"IS Investigators","year":"2012","unstructured":"Investigators IS, Chakravarthy U, Harding SP, Rogers CA, Downes SM, Lotery AJ, et al. Ranibizumab versus bevacizumab to treat neovascular age-related macular degeneration: one-year findings from the IVAN randomized trial. Ophthalmology. 2012;1197:1399\u2013411.","journal-title":"Ophthalmology"},{"key":"19_CR5","doi-asserted-by":"publisher","first-page":"2537","DOI":"10.1016\/j.ophtha.2012.09.006","volume":"11912","author":"JS Heier","year":"2012","unstructured":"Heier JS, Brown DM, Chong V, Korobelnik JF, Kaiser PK, Nguyen QD, et al. Intravitreal aflibercept (VEGF trap-eye) in wet age-related macular degeneration. Ophthalmology. 2012;11912:2537\u201348.","journal-title":"Ophthalmology"},{"issue":"11","key":"19_CR6","doi-asserted-by":"publisher","first-page":"2292","DOI":"10.1016\/j.ophtha.2013.03.046","volume":"120","author":"S Rofagha","year":"2013","unstructured":"Rofagha S, Bhisitkul RB, Boyer DS, Sadda SR, Zhang K, Group S-US. Seven-year outcomes in ranibizumab-treated patients in ANCHOR, MARINA, and HORIZON: a multicenter cohort study (SEVEN-UP). Ophthalmology. 2013;120(11):2292\u20139.","journal-title":"Ophthalmology"},{"key":"19_CR7","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1016\/j.ajo.2012.06.031","volume":"1551","author":"M Kruger Falk","year":"2013","unstructured":"Kruger Falk M, Kemp H, Sorensen TL. Four-year treatment results of neovascular age-related macular degeneration with ranibizumab and causes for discontinuation of treatment. Am J Ophthalmol. 2013;1551:89\u201395.","journal-title":"Am J Ophthalmol"},{"key":"19_CR8","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1016\/j.ophtha.2012.07.026","volume":"1201","author":"R Silva","year":"2013","unstructured":"Silva R, Axer-Siegel R, Eldem B, Guymer R, Kirchhof B, Papp A, et al. The SECURE study: long-term safety of ranibizumab 0.5 mg in neovascular age-related macular degeneration. Ophthalmology. 2013;1201:130\u20139.","journal-title":"Ophthalmology"},{"key":"19_CR9","doi-asserted-by":"publisher","first-page":"1175","DOI":"10.1016\/j.ophtha.2011.12.016","volume":"1196","author":"MA Singer","year":"2012","unstructured":"Singer MA, Awh CC, Sadda S, Freeman WR, Antoszyk AN, Wong P, et al. HORIZON: an open-label extension trial of ranibizumab for choroidal neovascularization secondary to age-related macular degeneration. Ophthalmology. 2012;1196:1175\u201383.","journal-title":"Ophthalmology"},{"issue":"12","key":"19_CR10","doi-asserted-by":"publisher","first-page":"2630","DOI":"10.1016\/j.ophtha.2013.05.018","volume":"120","author":"A Rasmussen","year":"2013","unstructured":"Rasmussen A, Bloch SB, Fuchs J, Hansen LH, Larsen M, Lacour M, et al. A 4-year longitudinal study of 555 patients treated with ranibizumab for neovascular age-related macular degeneration. Ophthalmology. 2013;120(12):2630\u20136.","journal-title":"Ophthalmology"},{"key":"19_CR11","doi-asserted-by":"publisher","first-page":"1469","DOI":"10.1136\/bjophthalmol-2012-302167","volume":"9612","author":"S Pushpoth","year":"2012","unstructured":"Pushpoth S, Sykakis E, Merchant K, Browning AC, Gupta R, Talks SJ. Measuring the benefit of 4\u00a0years of intravitreal ranibizumab treatment for neovascular age-related macular degeneration. Br J Ophthalmol. 2012;9612:1469\u201373.","journal-title":"Br J Ophthalmol"},{"key":"19_CR12","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.preteyeres.2008.10.001","volume":"281","author":"X Ding","year":"2009","unstructured":"Ding X, Patel M, Chan CC. Molecular pathology of age-related macular degeneration. Prog Retin Eye Res. 2009;281:1\u201318.","journal-title":"Prog Retin Eye Res"},{"key":"19_CR13","first-page":"2263","volume":"14","author":"I Chowers","year":"2008","unstructured":"Chowers I, Meir T, Lederman M, Goldenberg-Cohen N, Cohen Y, Banin E, et al. Sequence variants in HTRA1 and LOC387715\/ARMS2 and phenotype and response to photodynamic therapy in neovascular age-related macular degeneration in populations from Israel. Mol Vis. 2008;14:2263\u201371.","journal-title":"Mol Vis"},{"key":"19_CR14","first-page":"1829","volume":"14","author":"I Chowers","year":"2008","unstructured":"Chowers I, Cohen Y, Goldenberg-Cohen N, Vicuna-Kojchen J, Lichtinger A, Weinstein O, et al. Association of complement factor H Y402H polymorphism with phenotype of neovascular age related macular degeneration in Israel. Mol Vis. 2008;14:1829\u201334.","journal-title":"Mol Vis"},{"key":"19_CR15","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1038\/ng.2578","volume":"454","author":"LG Fritsche","year":"2013","unstructured":"Fritsche LG, Chen W, Schu M, Yaspan BL, Yu Y, Thorleifsson G, et al. Seven new loci associated with age-related macular degeneration. Nat Genet. 2013;454:433\u20139.","journal-title":"Nat Genet"},{"issue":"11","key":"19_CR16","doi-asserted-by":"publisher","first-page":"1366","DOI":"10.1038\/ng.2741","volume":"45","author":"JM Seddon","year":"2013","unstructured":"Seddon JM, Yu Y, Miller EC, Reynolds R, Tan PL, Gowrisankar S, et al. Rare variants in CFI, C3 and C9 are associated with high risk of advanced age-related macular degeneration. Nat Genet. 2013;45(11):1366\u201370.","journal-title":"Nat Genet"},{"key":"19_CR17","doi-asserted-by":"publisher","first-page":"1641","DOI":"10.1016\/j.ophtha.2013.01.014","volume":"1208","author":"F Abedi","year":"2013","unstructured":"Abedi F, Wickremasinghe S, Richardson AJ, Islam AF, Guymer RH, Baird PN. Genetic influences on the outcome of anti-vascular endothelial growth factor treatment in neovascular age-related macular degeneration. Ophthalmology. 2013;1208:1641\u20138.","journal-title":"Ophthalmology"},{"key":"19_CR18","doi-asserted-by":"publisher","first-page":"593","DOI":"10.1016\/j.ophtha.2012.11.037","volume":"1203","author":"SA Hagstrom","year":"2013","unstructured":"Hagstrom SA, Ying GS, Pauer GJ, Sturgill-Short GM, Huang J, Callanan DG, et al. Pharmacogenetics for genes associated with age-related macular degeneration in the Comparison of AMD Treatments Trials (CATT). Ophthalmology. 2013;1203:593\u20139.","journal-title":"Ophthalmology"},{"issue":"5-6","key":"19_CR19","doi-asserted-by":"publisher","first-page":"355","DOI":"10.3109\/08820538.2013.825292","volume":"28","author":"J Kanoff","year":"2013","unstructured":"Kanoff J, Miller J. Pharmacogenetics of the treatment response of age-related macular degeneration with ranibizumab and bevacizumab. Semin Ophthalmol. 2013;28(5-6):355\u20136.","journal-title":"Semin Ophthalmol"},{"key":"19_CR20","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1016\/j.ophtha.2012.10.006","volume":"1201","author":"F Abedi","year":"2013","unstructured":"Abedi F, Wickremasinghe S, Richardson AJ, Makalic E, Schmidt DF, Sandhu SS, et al. Variants in the VEGFA gene and treatment outcome after anti-VEGF treatment for neovascular age-related macular degeneration. Ophthalmology. 2013;1201:115\u201321.","journal-title":"Ophthalmology"},{"key":"19_CR21","doi-asserted-by":"publisher","first-page":"929","DOI":"10.2174\/15665240113139990048","volume":"136","author":"L Zhao","year":"2013","unstructured":"Zhao L, Grob S, Avery R, Kimura A, Pieramici D, Lee J, et al. Common variant in VEGFA and response to anti-VEGF therapy for neovascular age-related macular degeneration. Curr Mol Med. 2013;136:929\u201334.","journal-title":"Curr Mol Med"},{"key":"19_CR22","doi-asserted-by":"publisher","first-page":"2644","DOI":"10.1167\/iovs.09-4774","volume":"515","author":"S Grover","year":"2010","unstructured":"Grover S, Murthy RK, Brar VS, Chalam KV. Comparison of retinal thickness in normal eyes using Stratus and Spectralis optical coherence tomography. Invest Ophthalmol Vis Sci. 2010;515:2644\u20137.","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"19_CR23","doi-asserted-by":"publisher","first-page":"553","DOI":"10.1056\/NEJMoa072618","volume":"3576","author":"JR Yates","year":"2007","unstructured":"Yates JR, Sepp T, Matharu BK, Khan JC, Thurlby DA, Shahid H, et al. Complement C3 variant and the risk of age-related macular degeneration. N Engl J Med. 2007;3576:553\u201361.","journal-title":"N Engl J Med"},{"key":"19_CR24","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1016\/j.ajo.2009.03.006","volume":"1482","author":"S Grover","year":"2009","unstructured":"Grover S, Murthy RK, Brar VS, Chalam KV. Normative data for macular thickness by high-definition spectral-domain optical coherence tomography (spectralis). Am J Ophthalmol. 2009;1482:266\u201371.","journal-title":"Am J Ophthalmol"},{"key":"19_CR25","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1097\/NRL.0b013e318148c08e","volume":"136","author":"EJ Fox","year":"2007","unstructured":"Fox EJ, Vartanian TK, Zamvil SS. The immunogenicity of disease-modifying therapies for multiple sclerosis: clinical implications for neurologists. Neurologist. 2007;136:355\u201362.","journal-title":"Neurologist"},{"key":"19_CR26","doi-asserted-by":"publisher","first-page":"1391","DOI":"10.1212\/01.wnl.0000277457.17420.b5","volume":"6914","author":"PA Calabresi","year":"2007","unstructured":"Calabresi PA, Giovannoni G, Confavreux C, Galetta SL, Havrdova E, Hutchinson M, et al. The incidence and significance of anti-natalizumab antibodies: results from AFFIRM and SENTINEL. Neurology. 2007;6914:1391\u2013403.","journal-title":"Neurology"},{"key":"19_CR27","doi-asserted-by":"publisher","first-page":"1828","DOI":"10.1093\/rheumatology\/kem261","volume":"4612","author":"M Svenson","year":"2007","unstructured":"Svenson M, Geborek P, Saxne T, Bendtzen K. Monitoring patients treated with anti-TNF-alpha biopharmaceuticals: assessing serum infliximab and anti-infliximab antibodies. Rheumatology. 2007;4612:1828\u201334.","journal-title":"Rheumatology"},{"key":"19_CR28","doi-asserted-by":"publisher","first-page":"2199","DOI":"10.1016\/j.ophtha.2008.07.007","volume":"11512","author":"S Schaal","year":"2008","unstructured":"Schaal S, Kaplan HJ, Tezel TH. Is there tachyphylaxis to intravitreal anti-vascular endothelial growth factor pharmacotherapy in age-related macular degeneration? Ophthalmology. 2008;11512:2199\u2013205.","journal-title":"Ophthalmology"},{"key":"19_CR29","doi-asserted-by":"publisher","first-page":"723","DOI":"10.1097\/IAE.0b013e3181a2c1c3","volume":"296","author":"F Forooghian","year":"2009","unstructured":"Forooghian F, Cukras C, Meyerle CB, Chew EY, Wong WT. Tachyphylaxis after intravitreal bevacizumab for exudative age-related macular degeneration. Retina. 2009;296:723\u201331.","journal-title":"Retina"},{"key":"19_CR30","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1136\/bjo.2011.203893","volume":"961","author":"MS Eghoj","year":"2012","unstructured":"Eghoj MS, Sorensen TL. Tachyphylaxis during treatment of exudative age-related macular degeneration with ranibizumab. Br J Ophthalmol. 2012;961:21\u20133.","journal-title":"Br J Ophthalmol"},{"issue":"12","key":"19_CR31","doi-asserted-by":"publisher","first-page":"2637","DOI":"10.1016\/j.ophtha.2013.07.046","volume":"120","author":"AJ Lotery","year":"2013","unstructured":"Lotery AJ, Gibson J, Cree AJ, Downes SM, Harding SP, Rogers CA, et al. Pharmacogenetic associations with vascular endothelial growth factor inhibition in participants with neovascular age-related macular degeneration in the IVAN study. Ophthalmology. 2013;120(12):2637\u201343.","journal-title":"Ophthalmology"},{"key":"19_CR32","doi-asserted-by":"publisher","first-page":"e344","DOI":"10.1111\/j.1755-3768.2010.02080.x","volume":"894","author":"C Nischler","year":"2011","unstructured":"Nischler C, Oberkofler H, Ortner C, Paikl D, Riha W, Lang N, et al. Complement factor H Y402H gene polymorphism and response to intravitreal bevacizumab in exudative age-related macular degeneration. Acta Ophthalmol (Copenh). 2011;894:e344\u20139.","journal-title":"Acta Ophthalmol (Copenh)"},{"key":"19_CR33","doi-asserted-by":"publisher","first-page":"779","DOI":"10.2217\/pgs.12.53","volume":"137","author":"J Tian","year":"2012","unstructured":"Tian J, Qin X, Fang K, Chen Q, Hou J, Li J, et al. Association of genetic polymorphisms with response to bevacizumab for neovascular age-related macular degeneration in the Chinese population. Pharmacogenomics. 2012;137:779\u201387.","journal-title":"Pharmacogenomics"},{"key":"19_CR34","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1007\/s12177-010-9055-1","volume":"32","author":"D Imai","year":"2010","unstructured":"Imai D, Mori K, Horie-Inoue K, Gehlbach PL, Awata T, Inoue S, et al. CFH, VEGF, and PEDF genotypes and the response to intravitreous injection of bevacizumab for the treatment of age-related macular degeneration. J Ocul Biol Dis Inform. 2010;32:53\u20139.","journal-title":"J Ocul Biol Dis Inform"},{"key":"19_CR35","doi-asserted-by":"publisher","first-page":"2168","DOI":"10.1016\/j.ophtha.2007.09.008","volume":"11412","author":"MA Brantley Jr","year":"2007","unstructured":"Brantley Jr MA, Fang AM, King JM, Tewari A, Kymes SM, Shiels A. Association of complement factor H and LOC387715 genotypes with response of exudative age-related macular degeneration to intravitreal bevacizumab. Ophthalmology. 2007;11412:2168\u201373.","journal-title":"Ophthalmology"}],"container-title":["BMC Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s12886-015-0019-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12886-015-0019-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12886-015-0019-x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12886-015-0019-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,9,2]],"date-time":"2021-09-02T10:53:08Z","timestamp":1630579988000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcophthalmol.biomedcentral.com\/articles\/10.1186\/s12886-015-0019-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,4,11]]},"references-count":35,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2015,12]]}},"alternative-id":["19"],"URL":"https:\/\/doi.org\/10.1186\/s12886-015-0019-x","relation":{},"ISSN":["1471-2415"],"issn-type":[{"value":"1471-2415","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,4,11]]},"assertion":[{"value":"28 September 2014","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 March 2015","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 April 2015","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}],"article-number":"39"}}